Search the Newsreel

PTC Inc. (PTC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Inc. reported Q3 revenue of $600.05 million, a 6.8% year-over-year decline, missing the Zacks Consensus Estimate by 2.9%. The company's EPS of $1.58 also fell short of the $1.60 consensus estimate. Key metrics like recurring revenue and total software revenue were below analyst …

PTC (NASDAQ:PTC) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Earnings Flash (PTC) PTC Inc. Reports Q3 Revenue $600.0M, vs. FactSet Est of $611.6M

PTC Inc. reported its Q3 revenue at $600.0 million, falling short of the FactSet estimate of $611.6 million. The company also provided guidance for Q4, expecting adjusted EPS to range from $1.63 to $2.21 and revenue to be between $630.0 million and $690.0 million. …

PTC Inc.: Fiscal Q3 Earnings Snapshot

PTC Inc. reported fiscal third-quarter net income of $118.8 million, or $1.03 per share, with adjusted earnings of $1.58 per share, which fell short of analysts' expectations. The product development software maker also missed revenue forecasts, posting $600 million against an expected $618 million. …

PTC Inc. (NASDAQ: PTC) lifts 2026 outlook on Q3 ARR and cash flow

PTC Inc. reported Q3 2026 results with a 7% year-over-year revenue decrease but raised its full-year 2026 guidance for constant-currency ARR, revenue, and EPS due to strong cash generation and exceeding prior guidance for operating and free cash flow. The company also aggressively repurchased …

PTC in the spotlight as earnings loom after portfolio pivot By Investing.com

PTC Inc. is approaching its fiscal third-quarter earnings report, where investors will assess the impact of its strategic pivot away from the Internet of Things business. Analysts forecast declines in EPS and revenue for the quarter, but their consensus remains constructive with a significant …

PTC|PTC Inc|Price:127.550|Chg%:+2.340

This article provides a detailed financial analysis and market trends for PTC Inc (PTC), a global software company. It highlights the company's strong fundamentals, high growth potential, and current valuation, which is considered fairly valued within the Software & IT Services industry. The report …

Renaissance Technologies LLC Sells 74,289 Shares of PTC Therapeutics, Inc. $PTCT

Renaissance Technologies LLC has reduced its stake in PTC Therapeutics, Inc. by 12.2%, selling 74,289 shares and now owning 533,300 shares valued at $36.33 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. PTC Therapeutics' stock opened at $75.39, with …

PTC Inc (PTC) Institutional Confidence

PTC Inc. (PTC) has an institutional shareholding score of 10.00, placing it first in the Software & IT Services industry. Institutional holdings have increased by 3.73% quarter-over-quarter, with the largest shareholder being ETHSX. The article details major institutional holders and their changes in shareholding.

PTC Inc. (PTC) Q3 Earnings and Revenues Miss Estimates

PTC Inc (PTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PTC Inc (PTC), detailing its current price momentum, support and resistance levels, and insights from various technical indicators and moving averages. The stock recently closed at $127.55, showing some positive movement. While some indicators suggest a neutral …

Zscaler, Shopify, and PTC Shares Skyrocket, What You Need To Know

Shares of Zscaler, Shopify, and PTC experienced significant jumps following a decline in Treasury yields and renewed market interest in enterprise software. This shift occurred as investors reallocated capital from the chip sector, which saw a selloff due to AI infrastructure spending concerns, towards …

PTC Therapeutics, Inc. $PTCT Shares Bought by Rock Springs Capital Management LP

Rock Springs Capital Management LP significantly increased its stake in PTC Therapeutics (PTCT) by 161.5% in the first quarter, now holding 161,798 shares valued at $11 million. This comes as PTC Therapeutics reported strong Q1 revenue of $272.55 million, a 43.5% year-over-year increase, and …

PTC Therapeutics (PTCT) Receives a Hold from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on PTC Therapeutics (PTCT) and set a price target of $85.00. Despite a Strong Buy consensus among analysts with an average price target of $98.64, the company reported a GAAP net loss in its latest …

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Evaluating a 26.74% Potential Upside Amidst Volatile Revenue Growth

PTCT|PTC Therapeutics Inc|Price:75.790|Chg%:-1.030

This article provides a comprehensive stock analysis of PTC Therapeutics Inc (PTCT) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis also covers institutional confidence, analyst ratings, and the company's product portfolio, emphasizing …

PTC Inc|Price:125.230|Chg%:+6.710

TradingKey provides a comprehensive analysis of PTC Inc (PTC), highlighting its strong fundamentals, high growth potential, and fair valuation within the Software & IT Services industry. The stock currently has a "Buy" rating from multiple analysts, with a target price suggesting significant upside. Although …

Orbimed Advisors LLC Has $3.35 Million Stake in PTC Therapeutics, Inc. $PTCT

Orbimed Advisors LLC significantly increased its stake in PTC Therapeutics (NASDAQ:PTCT) by 111.6% in the first quarter, now holding 49,100 shares valued at approximately $3.35 million. This increase comes despite recent insider selling by two executives totaling $3.61 million and other insider sales amounting …

PTC Inc (PTC) Shares Surge 5.6% -- What GF Score of 81 Tells Inv

PTC Inc (PTC) shares surged 5.6% following a period of high volatility, with its current price significantly below its GF Value, indicating undervaluation. The company boasts a strong GF Score of 81/100, driven by high profitability and growth scores, despite a low momentum score …

Barclays Maintains PTC Inc(PTC.US) With Buy Rating, Maintains Target Price $150

Barclays has reiterated its Buy rating for PTC Inc. (PTC.US) and maintained its price target of $150. This indicates a continued positive outlook from the firm regarding PTC Inc.'s stock performance.

PTC Inc. stock underperforms Monday when compared to competitors despite daily gains

PTC Inc. (PTC) stock gained 5.64% on Monday, closing at $125.21, marking its second consecutive day of increases. Despite this gain, the stock underperformed compared to the broader market, as the S&P 500 Index rose by 0.02% and the Dow Jones Industrial Average increased …

PTC Therapeutics Inc (PTCT) Balance Sheet

This article provides the quarterly and annual balance sheet data for PTC Therapeutics Inc (PTCT), allowing users to analyze its financial health, liquidity, leverage, and return on equity. It includes detailed financial figures for various assets, liabilities, and shareholders' equity categories spanning multiple years …

PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says

RBC Capital Markets conducted a physician survey regarding PTC Therapeutics' drug Sephience for phenylketonuria (PKU). The survey results were mixed, indicating some positive feedback but also highlighting challenges in the drug's launch momentum. This suggests that while there's potential, the uptake of Sephience might …

PTC Inc (PTC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of PTC Inc (PTC), highlighting major institutional holders and their proportion of shares. It provides a breakdown of shareholder types and traces institutional shareholding over recent quarters, alongside listing prominent institutions and their recent activity. The content also …

PTC Inc. $PTC Stake Decreased by Lazard Asset Management LLC

Lazard Asset Management LLC reduced its stake in PTC Inc. (NASDAQ:PTC) by 13.5% in the first quarter, selling 204,612 shares. Despite this, several other institutional investors increased their holdings in PTC during recent quarters. The company reported strong Q1 earnings, beating analyst estimates, and …

Renaissance Technologies LLC Buys 183,600 Shares of PTC Inc. $PTC

Renaissance Technologies LLC increased its stake in PTC Inc. by 89.3% in the first quarter, now owning 389,100 shares valued at $55.44 million. Other hedge funds also adjusted their positions in PTC, with institutional investors collectively owning 95.14% of the company's stock. Analysts have …

PTC Therapeutics Inc (PTCT) Shareholder Structure: Major Shareholders & Institutional Holdings

The article details the shareholder structure of PTC Therapeutics Inc (PTCT), highlighting its major shareholders and institutional holdings. It provides a breakdown of significant institutional investors like BlackRock and RTW Investments, along with analysis of shareholder types and changes in institutional shareholding over recent …

PTC Therapeutics Inc (PTCT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides a dividend and stock split report for PTC Therapeutics Inc (PTCT). It states that the company has not distributed any dividends over the past five years. The page includes current stock information such as share price, market cap, and …

PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PTC Therapeutics Inc (PTCT), showing a current earnings forecast score of 7.50, ranking 101 out of 155 in the Pharmaceuticals industry. Analysts have set an average price target of $80.00, with a majority recommending a "Buy" for …

PTC Therapeutics, Inc. Revenue Breakdown – BOATS:PTCT

PTC Therapeutics, Inc. (PTCT) generated $1.73 billion in revenue last year, with its Life Science segment being the primary contributor, also at $1.73 billion. The United States was the leading geographical source of revenue, accounting for $1.49 billion. This data highlights the company's key …

PTC Inc. (PTC) Q2 2024 Earnings Report - Results, Call & Slides

PTC Inc. reported strong Q2 2024 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of $25.56 against a consensus of $21.48, and actual revenue of $10.56 billion against an expected $10.11 billion, representing an 11.23% year-over-year revenue growth. PTC's …

A Look at PTC Inc (PTC) After 5.0% Gain -- GF Value $215.29 vs P

PTC Inc (PTC) shares rose 5.0% today, reaching $118.52, but remain down significantly year-to-date and over the past year. GuruFocus assesses PTC as significantly undervalued with a GF Value of $215.29, despite a strong GF Score of 81/100 for financial health and growth potential. …

How Investors Are Reacting To PTC (PTC) Hospital-Based 3D Printing Collaboration And AI-Driven CAD Narrative

PTC Inc. has announced a collaboration with Rambam Health Care Campus and EOS GmbH to establish a Digital Implant Engineering Center, integrating 3D printing with PTC’s Creo CAD tools for customized medical implants. This initiative highlights the potential for personalized medical treatments through digital …

Earnings Preview: PTC Inc to Report Financial Results Post-market on July 29

PTC Inc (NYSE:PTC) is scheduled to report its quarterly financial results after the market closes on July 29. Analysts are forecasting earnings of $1.09 per share, with revenue expectations at $587.89 million, representing a significant year-over-year increase. The report will provide insight into the …

PTC Inc. Stock Slips 6.3%, Underperforms Peers

PTC Inc. stock experienced a 6.3% decline, leading to underperformance compared to its peers. The article, sourced from Dow Jones, notes this dip in the company's financial standing. Further details require logging into the Webull platform.

PTCT5396017 Bond Profile — Key Metrics

This article provides a detailed profile of the PTCT5396017 bond issued by PTC Therapeutics, Inc. Key metrics include its 1.5% coupon rate, an issue date of April 8, 2022, and a maturity date of September 15, 2026. The biopharmaceutical company focuses on rare disorders …